Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 May 8;13(9):2266.
doi: 10.3390/cancers13092266.

Advances and Perspectives in the Treatment of B-Cell Malignancies

Marta Cuenca  1 , Victor Peperzak  1
Affiliations
Editorial

Advances and Perspectives in the Treatment of B-Cell Malignancies

Marta Cuenca et al. Cancers (Basel). .

Abstract

B-cell malignancies arise from different stages of B-cell differentiation and constitute a heterogeneous group of cancers including B-cell lymphomas, B-cell leukemias, and plasma cell dyscrasias [...].

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Montironi C., Muñoz-Pinedo C., Eldering E. Hematopoietic versus solid cancers and T cell dysfunction: Looking for similarities and distinctions. Cancers. 2021;13:284. doi: 10.3390/cancers13020284. - DOI - PMC - PubMed
    1. Van Bruggen J.A.C., Martens A.W.J., Tonino S.H., Kater A.P. Overcoming the hurdles of autologous t-cell-based therapies in b-cell non-hodgkin lymphoma. Cancers. 2020;12:3837. doi: 10.3390/cancers12123837. - DOI - PMC - PubMed
    1. Van der Horst H.J., Nijhof I.S., Mutis T., Chamuleau M.E.D. Fc-engineered antibodies with enhanced fc-effector function for the treatment of b-cell malignancies. Cancers. 2020;12:3041. doi: 10.3390/cancers12103041. - DOI - PMC - PubMed
    1. Armengol M., Santos J.C., Fernández-serrano M., Profitós-pelejà N., Ribeiro M.L., Roué G. Immune-checkpoint inhibitors in B-cell lymphoma. Cancers. 2021;13:214. doi: 10.3390/cancers13020214. - DOI - PMC - PubMed
    1. Vera de Jonge A., Mutis T., Roemer M.G.M., Scheijen B., Chamuleau M.E.D. Impact of myc on anti-tumor immune responses in aggressive b cell non-hodgkin lymphomas: Consequences for cancer immunotherapy. Cancers. 2020;12:3052. doi: 10.3390/cancers12103052. - DOI - PMC - PubMed

Publication types

LinkOut - more resources